Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up

医学 美罗华 强的松 环磷酰胺 四分位间距 内科学 胃肠病学 膜性肾病 单中心 肌酐 外科 泌尿科 肾小球肾炎 化疗 肾 淋巴瘤
作者
Reza Zonozi,Karen Laliberte,Noah Huizenga,Jillian K. Rosenthal,Anushya Jeyabalan,A. Bernard Collins,Frank B. Cortazar,John L. Niles
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:78 (6): 793-803 被引量:53
标识
DOI:10.1053/j.ajkd.2021.04.014
摘要

B-cell depletion with rituximab has emerged as a first-line therapy for primary membranous nephropathy (MN). However, most patients do not achieve complete remission with rituximab monotherapy. In this case series, we report longer-term remission and relapse rates, anti-phospholipase A2 receptor (PLA2R) antibody levels, B-cell levels, and serious adverse events in patients with primary MN who received rituximab combined with an initial short course of low-dose oral cyclophosphamide and a course of rapidly tapered prednisone.Single-center retrospective case series.60 consecutive patients with primary MN treated with the combination of rituximab, low-dose cyclophosphamide, and prednisone at the Vasculitis and Glomerulonephritis Center at the Massachusetts General Hospital.After treatment initiation, median follow-up was 38 (interquartile range [IQR], 25-62) months; 100% of patients achieved partial remission, defined as a urinary protein-creatinine ratio (UPCR) < 3 g/g and a 50% reduction from baseline, at a median of 3.4 months. By 2 years after treatment initiation, 83% achieved complete remission, defined as a UPCR < 0.3 g/g. The median time to complete remission was 12.4 months. Immunologic remission (defined by an anti-PLA2R titer < 14 RU/mL) was achieved by 86% and 100% of anti-PLA2R seropositive patients (n = 29) at 3 and 6 months, respectively, after treatment initiation. After 1 year, the median UPCR fell from 8.4 (IQR, 5.0-10.7) to 0.3 (IQR, 0.2-0.8) g/g (P < 0.001). No patient relapsed throughout the duration of B-cell depletion. Relapse occurred in 10% of patients at 2 years after the onset of B-cell reconstitution following the last rituximab dose. Over a combined follow-up time of 228 patient-years, 18 serious adverse events occurred. One death occurred unrelated to treatment or primary MN, and 1 patient progressed to kidney failure requiring kidney replacement therapy.Absence of a comparison group.All patients with primary MN treated with combination therapy achieved partial remission and most achieved a durable complete remission with an acceptable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
单纯的剑封完成签到 ,获得积分10
1秒前
小二郎的应助被丁亦竹采纳,获得100
1秒前
2秒前
春风完成签到 ,获得积分10
2秒前
黑囡发布了新的文献求助10
3秒前
3秒前
榴莲姑娘完成签到 ,获得积分10
3秒前
4秒前
Hello的应助被机智的方盒采纳,获得10
4秒前
洋气天天完成签到,获得积分10
6秒前
烟花的应助被捉闰土的猹采纳,获得10
7秒前
panpanou发布了新的文献求助20
8秒前
Hui发布了新的文献求助10
8秒前
9秒前
JamesPei的应助被风中巧凡采纳,获得10
10秒前
kcaj完成签到,获得积分0
10秒前
11秒前
1103完成签到,获得积分10
12秒前
顾矜的应助被maryin采纳,获得10
12秒前
12秒前
lindan完成签到 ,获得积分10
13秒前
13秒前
orange发布了新的文献求助10
13秒前
吃不饱发布了新的文献求助10
15秒前
molihuakai的应助被chen7402采纳,获得10
15秒前
16秒前
是希希啊a发布了新的文献求助10
16秒前
fairy完成签到 ,获得积分10
16秒前
Orange的应助被cs采纳,获得10
16秒前
WYT发布了新的文献求助10
17秒前
顾矜的应助被爱听歌飞丹采纳,获得30
17秒前
Dddd完成签到,获得积分20
18秒前
19秒前
冬晨1986完成签到,获得积分10
20秒前
wu完成签到,获得积分10
21秒前
乐乐的应助被lixu采纳,获得10
21秒前
潇洒哥暴打黑大帅完成签到,获得积分10
22秒前
Haiser完成签到,获得积分10
22秒前
23秒前
子星完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621